*MenB, serogroup B meningococcal; MenB-4C, Bexsero (GlaxoSmithKline, https://www.gsk.com); MenB-FHbp, Trumenba (Pfizer, https://www.pfizer.com); NA, vaccination coverage estimates not available.
†Vaccine available through a CDC-sponsored investigational new drug protocol.
‡Coverage data refer to 2015 campaign. Incoming freshmen and returning study abroad students were also vaccinated in 2015–2016.
§MenB-4C was also used in response to this outbreak; 21% of students completed either vaccine series. Presented coverage data for this university are as of July 2018.
¶One case in each of these outbreaks occurred 6 days after MenB vaccination efforts commenced, thus prior to any expected immunity.
#This coverage estimate represents the number of persons vaccinated in the second campaign, which likely included some first doses.
**Reported coverage reflects only vaccine doses given on campus; additional students received vaccine doses from providers or pharmacies at home or in other states.
††Cases occurred at 2 universities in a college consortium in the same geographic area. The first 2 cases occurred at university 1 and the third case occurred at university 2. Both universities began vaccination efforts following the second case.
‡‡Combined first-dose coverage data for both universities are presented in the table. First-dose coverage was 33% at university 1 (23,388 undergraduates) and 41% at university 2 (2,500 undergraduates) (Figure 2). Vaccination was ongoing at the time of publication; therefore, data should be considered preliminary.